WS #15694
Healthcare and biotech sectors are outperforming the broader market, with IBB and XBI gaining 3.0% and individual names like MRNA (+14.21%) and ZS (+7.80%) posting significant gains. This leadership in software and healthcare indicates a rotation into defensive growth assets, likely driven by the FDA's recent approvals and a flight to quality amid geopolitical uncertainty. The trend is broad-based, affecting both large-cap pharma and mid-cap software.
Healthcare & Biotech Momentum
Healthcare and biotech sectors are outperforming the broader market, with IBB and XBI gaining 3.0% and individual names like MRNA (+14.21%) and ZS (+7.80%) posting significant gains. This leadership in software and healthcare indicates a rotation into defensive growth assets, likely driven by the FDA's recent approvals and a flight to quality amid geopolitical uncertainty. The trend is broad-based, affecting both large-cap pharma and mid-cap software.